Home ETF List About

ETF Holdings Breakdown of INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

INCY institutional holdings

The following institutional investment holdings of INCY have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-23 IE00B5BMR087 (iShares Core S&P 500 UCITS ETF USD (Acc)) 379,253 0.0%USD 33,871,085 1.4%
2025-10-23 IE00BD8KRH84 (iShares Core S&P 500 UCITS ETF GBP Hedged (Dist)) 379,253USD 33,871,085
2025-10-23 IE00BL3J3G74 (iShares Core S&P 500 UCITS ETF MXN Hedged (Acc)) 379,253 0.0%USD 33,871,085 1.4%
2025-10-23 IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc)) 255,162USD 22,788,518
2025-10-23 IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist)) 255,162USD 22,788,518 1.4%
2025-10-23 IE00BKBF6H24 (iShares Core MSCI World UCITS ETF) 255,162USD 22,788,518
2025-10-23 IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist)) 255,162USD 22,788,518 1.4%
2025-10-22 IE00BHZPJ890 (iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)) 41,466 2.5%USD 3,651,496 3.3%
2025-10-22 IE0031442068 (iShares Core S&P 500 UCITS ETF USD (Dist)) 57,096 0.0%USD 5,027,874 0.8%
2025-10-23 IE00BYX2JD69 (iShares MSCI World SRI UCITS ETF) 86,091USD 7,688,787
2025-10-23 IE00BMZ17T93 (iShares MSCI World SRI UCITS ETF GBP Hedged (Dist) GBP) 86,091USD 7,688,787
2025-10-23 IE00BMZ17X30 (iShares MSCI World SRI UCITS ETF USD Hedged (Dist)) 86,091USD 7,688,787
2025-10-23 IE00BFNM3G45 (iShares MSCI USA ESG Screened UCITS ETF USD (Acc)) 48,235USD 4,307,868
2025-10-23 IE00BFNM3H51 (iShares MSCI USA ESG Screened UCITS ETF USD (Dist)) 48,235USD 4,307,868
2025-10-23 IE000G2LIHG9 (iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc)) 48,235USD 4,307,868 1.4%
2025-10-23 IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist)) 21,250USD 1,897,838
2025-10-23 IE00BYVJRR92 (iShares MSCI USA SRI UCITS ETF USD (Acc)) 46,903USD 4,188,907
2025-10-23 IE00BZ173V67 (iShares MSCI USA SRI UCITS ETF EUR Hedged (Dist)) 46,903USD 4,188,907
2025-10-23 IE00BZ173T46 (iShares MSCI USA SRI UCITS ETF USD (Dist)) 46,903 -0.1%USD 4,188,907 1.3%
2025-10-23 IE00BMWPV470 (iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist)) 46,903 -0.1%USD 4,188,907 1.3%
2025-10-23 IE00B3ZW0K18 (iShares S&P 500 EUR Hedged UCITS ETF (Acc)) 23,693USD 1,821,958
2025-10-23 IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP) 4,265USD 380,907
2025-10-23 IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP) 4,265USD 380,907
2025-10-23 IE00BP3QZB59 (iShares Edge MSCI World Value Factor UCITS ETF) 29,492USD 2,633,931
2025-10-23 IE00BFYTYS33 (iShares Edge MSCI World Value Factor UCITS USD Dist) 29,492USD 2,633,931 1.4%
2025-10-23 IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist)) 11,014 0.5%USD 983,660 4.0%
2025-10-23 IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF) 11,014USD 983,660
2025-10-23 IE0003WV2ME7 (iShares S&P 500 Equal Weight UCITS ETF GBP Hedged (Acc)) 96,376 -0.1%USD 8,607,341 1.3%
2025-10-23 IE000MLMNYS0 (iShares S&P 500 Equal Weight UCITS ETF USD (Acc)) 96,376 -0.1%USD 8,607,341 1.3%
2025-10-23 IE00B8FHGS14 (iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Acc)) 112,969USD 10,089,261
2025-10-23 IE00BGPP8L80 (iShares Edge MSCI World Minimum Volatility UCITS ETF GBP Hedged (Acc)) 112,969USD 10,089,261 1.4%
2025-10-23 IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc)) 9,400USD 722,847
2025-10-23 IE00B43HR379 (iShares S&P 500 Health Care Sector UCITS ETF USD (Acc)) 81,358USD 7,266,083
2025-10-23 IE00BMBKBZ46 (iShares S&P 500 Health Care Sector UCITS ETF) 81,358USD 7,266,083 1.4%
2025-10-23 IE00B52SFT06 (iShares MSCI USA UCITS ETF USD (Acc)) 8,124USD 725,554
2025-10-23 IE00B6SPMN59 (iShares Edge S&P 500 Minimum Volatility UCITS ETF USD (Acc)) 92,266USD 8,240,276
2025-10-23 IE00BD93YH54 (iShares Edge S&P 500 Minimum Volatility UCITS ETF USD (Dist)) 92,266USD 8,240,276
2025-10-22 IE00B14X4M10 (iShares MSCI North America UCITS ETF USD (Dist) USD) 3,902USD 343,610 0.9%
2025-10-23 IE0002W8NB38 (iShares MSCI USA Swap UCITS ETF USD (Acc)) 5,446USD 486,382
2025-10-23 IE00BKVL7778 (iShares Edge MSCI World Minimum Volatility ESG UCITS ETF USD (Acc)) 31,599USD 2,822,107
2025-10-23 IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF) 3,257USD 290,883
2025-10-23 IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc)) 3,257USD 290,883
2025-10-23 IE00BMXC7V63 (iShares S&P 500 Paris-Aligned Climate UCITS ETF USD (Acc)) 1,034 -1.2%USD 92,347 0.3%
2025-10-23 IE000G4PH2B1 (iShares S&P 500 Paris-Aligned Climate UCITS ETF USD Dist) 1,034USD 92,347
2025-10-23 IE00B3Y8X563 (iShares S&P 500 GBP Hedged UCITS ETF (Acc)) 3,633USD 243,545 1.6%
2025-10-23 IE000R9FA4A0 (iShares S&P 500 ESG UCITS ETF USD (Acc)) 2,897USD 258,731
2025-10-23 IE00BN92ZL31 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist)) 910USD 81,272
2025-10-23 IE00BMXC7W70 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Acc)) 910USD 81,272
2025-10-23 IE00BKVL7331 (iShares Edge MSCI USA Minimum Volatility ESG UCITS ETF USD (Acc)) 6,279USD 560,777 1.4%
2025-10-23 IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc)) 1,057USD 70,858
2025-10-23 IE00BP3QZD73 (iShares MSCI World Mid-Cap Equal Weight UCITS ETF USD (Acc)) 6,598USD 589,267
2025-10-23 IE00BD1F4K20 (iShares MSCI USA Mid-Cap Equal Weight UCITS ETF USD (Acc)) 14,358USD 1,282,313
2025-10-23 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 678USD 60,552 1.4%
2025-10-23 IE00013A2XD6 (iShares MSCI ACWI SRI UCITS ETF USD(Dist)) 911USD 81,361
2025-10-23 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 1,000USD 89,310
2025-10-23 IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc) 618USD 55,194
2025-10-23 IE000F9IDGB5 (iShares MSCI World Swap UCITS ETF USD (Acc)) 45,449 200.0%USD 4,059,050 198.6%
2025-10-23 IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc)) 5,651USD 504,691
2025-10-23 IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc)) 12,835USD 1,146,294
2025-10-23 IE000YNE6S57 (iShares MSCI World Climate Transition Aware UCITS ETF USD (Dist)) 27USD 2,411
2025-10-23 IE0001YGXFO5 (iShares MSCI World Climate Transition Aware UCITS ETF USD (Acc)) 27USD 2,411
2025-10-23 IE000YG82CF0 (iShares MSCI USA Climate Transition Aware UCITS ETF USD (Dist)) 24USD 2,143
2025-10-23 IE000MGAVJV3 (iShares MSCI USA Climate Transition Aware UCITS ETF USD (Acc)) 24USD 2,143
2025-10-23 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 123,032USD 10,987,988
2025-10-23 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 123,032USD 10,987,988
2025-10-22 IE00B6R52259 (iShares MSCI ACWI UCITS ETF) 57,778USD 5,087,931 0.9%
2025-10-23 IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc)) 57,778USD 5,160,153
Total =4,280,541 USD 381,579,619
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
SG Americas Securities LLC Reduces Stake in Incyte Co. (NASDAQ:INCY)
SG Americas Securities LLC lowered its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 60.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,130 shares of the biopharmaceutical company’s stock after selling 60,277 shares during the period. […] - 2025-06-15 06:28:55

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.